Company Overview
Company Type: Private Company
Company Status: Operating Subsidiary
Website: www.igenomix.eu
Number of Employees: 550
Year Founded: 2009
Total Amount Raised (CAD mm)†: -
Total Rounds of Funding**:1
Latest Post-Money Valuation ($ mm) -
Latest Pre-Money Valuation ($ mm) -
† This number reflects the estimated value of the total new money raised through private placement rounds.
** This value is an estimate of the total number of funding rounds this company has received.


Business Description
Igenomix S.L. operates as a medical analysis laboratory, which offers reproductive genetics testing services. The company provides EndomeTRIO, an endometrial analysis; PGT-A + ERA synchrony, a test that enables users to choose genetically normal embryos to transfer into a genetically optimal uterus; products of conception, an analysis of fetal tissue using next-generation sequencing technology that screens the 46 chromosomes and determines if a chromosomal abnormality is present; and Oncodona, a genetic test for early identification of predisposition to inherited cancer. It also offers endometrial microbiome metagenomic analysis, analysis of infectious chronic endometritis, preimplantation genetic testing for aneuploidies, family balancing, embryo analysis of culture environment, preimplantation genetic testing for monogenic disorders, and sperm aneuploidy test. It has laboratories worldwide. Igenomix S.L. was incorporated in 2009 and is based in Paterna, Spain with an additional office in Miami, Florida. As of September 23, 2022, Igenomix S.L. operates as a subsidiary of Mendel Holdco S.L.


Financial Information (Currency: CAD, in mm)
Total Revenue
 13.2
Operating Income
 (11.6)
Total Assets
 511.5
Gross Profit
 4.8
EBITDA
 (2.3)
Total Debt
 110.0
Net Income
 (8.0)
Estimated Number of Employees
 550
Net Debt
 107.8
Private Co. Financial Data  as of Jun-30-2021. * Hover over data point numbers for date and source.

Key Professionals
Name
Title
Bonilla, Borja Aznar
Managing Director of USA & Canada
Herrera, Francisco Rodriguez
Senior Vice President of Affiliates


Primary Industry Classification
Health Care Services


Primary Office Location
Ronda Narciso Monturiol, 11 B Parque Tecnológico Paterna | Paterna, Valencian Community | 46980 | Spain
Phone: 34 963 90 53 10   Fax: 34 963 90 25 22

Parent Company
Mendel Holdco S.L

Prior Investors
Aleph Capital, S.G.E.I.C., S.A., Amadeus Capital Partners Limited (Andrea Traversone), Charme Capital Partners SGR S.p.A., Charme III, Dapala 2014 S.L., EQT Partners AB, EQT VIII, Eurazeo Investment Manager, Toverdans S.L.


Company Notes
No Company Notes exist.


Strategy Notes
No Strategy Notes exist.


Current and Pending Subsidiaries / Investments
Company Name
Business Description
Geography
Primary Industry
LTM Total Rev.($mm)
LFQ Total Assets ($mm)
LFQ Total Debt ($mm)
Access Genomics Inc.
Access Genomics Inc. operates as a clinical genomics company. The company offers genomics, molecular biology, embryology, and screening for diagnostics. Its services include preimplantation genetic testing for aneuploidy, non-invasive prenatal testing, genetic counselling, and products of conception testing. The company was incorporated in 2016 and is based in Mississauga, Canada. As of December 14, 2020, Access Genomics Inc. operates as a subsidiary of Igenomix, S.L.

United States and Canada
Health Care Services
-
-
-


Last 5 Transactions
Announced Date
Closed Date
Transaction Type
Role
Target
Buyer/Investors
Sellers
Size($mm)
Jul-08-2021
Nov-30-2021
Merger/Acquisition
Target
Igenomix S.L.
Vitrolife AB (publ) (OM:VITR)
EQT Partners AB Seller Funds:EQT VIII
1,480.69
Dec-17-2020
Dec-14-2020
Merger/Acquisition
Buyer
Access Genomics Inc.
Igenomix S.L.
PCP GP, L.P.
-
Mar-28-2019
Jun-30-2019
Merger/Acquisition
Target
Igenomix S.L.
Charme Capital Partners SGR S.p.A.,EQT Partners AB Buyer Funds:EQT VIII
Charme Capital Partners SGR S.p.A. Seller Funds:Charme III
-
Aug-08-2016
Aug-08-2016
Private Placement
Target
Igenomix S.L.
Charme Capital Partners SGR S.p.A.,Amadeus Capital Partners Limited,Aleph Capital, S.G.E.I.C., S.A. Buyer Funds:Charme III

-
Jul-19-2016
Jul-19-2016
Merger/Acquisition
Target
Igenomix S.L.
Charme Capital Partners SGR S.p.A. Buyer Funds:Charme III
Toverdans S.L.,Dapala 2014 S.L.
-
* denotes that the relationship is proprietary


Last 5 Key Developments
Date
Event Type
Headline
Nov-30-2021
M&A Transaction Closings
Vitrolife AB (publ) (OM:VITR) completed the acquisition of Igenomix, S.L. from EQT VIII, a fund managed by EQT Partners AB.
Jul-09-2021
M&A Calls
Igenomix, S.L., Vitrolife AB (publ) - M&A Call
Jul-08-2021
M&A Transaction Announcements
Vitrolife AB (publ) (OM:VITR) entered into an agreement to acquire Igenomix, S.L. from EQT VIII, a fund managed by EQT Partners AB.
Dec-17-2020
M&A Transaction Closings
Igenomix, S.L. acquired Access Genomics from PCP GP, L.P.
Jun-04-2020
Strategic Alliances
Ferring Pharmaceuticals and Igenomix Collaborate to Advance Care in Reproductive Medicine and Maternal Health

Competitors
CooperSurgical, Inc., Genetics Generation Advancement Corp. (TPEX:4160), Good Start Genetics, Inc., Invitae Corporation (NYSE:NVTA), Myriad Women's Health, Inc. (Acquired), Natera, Inc. (NasdaqGS:NTRA)

M&A Advisors
Allen & Overy Spain, Arcano Asesores Financieros, S.L., Deloitte S.L., J&A Garrigues, S.L.P., J.P. Morgan Espana S.A., Morgan Stanley (NYSE:MS), White & Case LLP


Advisors
M&A Advisors
Allen & Overy Spain, Arcano Asesores Financieros, S.L., Deloitte S.L., J&A Garrigues, S.L.P., J.P. Morgan Espana S.A., Morgan Stanley (NYSE:MS), White & Case LLP


Last 10 Investment Research Documents
Contributor
Analyst
Date/Time
Company
Headline
Type
Pages
Infinata, Inc.
Infinata Research
Mar 09, 2021 06:16 AM
Igenomix S.L.
Igenomix, S.L. - Company Report
Reports
9
Infinata, Inc.
Infinata Research
Dec 29, 2020 01:20 AM
Igenomix S.L.
Igenomix, S.L. - Company Report
Reports
9
Infinata, Inc.
Infinata Research
Aug 19, 2020 09:33 AM
Igenomix S.L.
Igenomix, S.L. - Company Report
Reports
8
Infinata, Inc.
Infinata Research
Jun 16, 2020 05:52 AM
Igenomix S.L.
Igenomix, S.L. - Company Report
Reports
8
Infinata, Inc.
Infinata Research
Mar 19, 2020 06:30 AM
Igenomix S.L.
Igenomix, S.L. - Company Report
Reports
8
Infinata, Inc.
Infinata Research
Dec 16, 2019 05:39 AM
Igenomix S.L.
Igenomix, S.L. - Company Report
Reports
8
Infinata, Inc.
Infinata Research
Sep 30, 2019 05:27 AM
Igenomix S.L.
Igenomix, S.L. - Company Report
Reports
8
Infinata, Inc.
Infinata Research
Jun 17, 2019 09:05 AM
Igenomix S.L.
Igenomix, S.L. - Company Report
Reports
8
Infinata, Inc.
Infinata Research
Mar 25, 2019 04:42 AM
Igenomix S.L.
Igenomix, S.L. - Company Report
Reports
7
GlobalData

Feb 09, 2017 05:17 AM
Igenomix S.L.
Reproductive Genetics to Enable Higher Success Rates and Prevent Transmission of Genetic Disorders: Igenomix
Reports
2


S&P Global Ratings Credit Ratings
No S&P Global Ratings Credit Ratings data available. 


News Headlines
No News is currently available for the selected sources.


Company Coverage
This company is not on any Coverage List.

Key Executives and Professionals Details
Name
Title
Phone
Fax
Email
Bonilla, Borja Aznar
Managing Director of USA & Canada
34 963 90 53 10
34 963 90 25 22

Herrera, Francisco Rodriguez
Senior Vice President of Affiliates
34 963 90 53 10
34 963 90 25 22

* denotes that the relationship is proprietary

S&P Credit Ratings and Research provided by 
No content (including ratings, credit-related analyses and data, valuations, model, software or other application or output therefrom) or any part thereof (Content) may be modified, reverse engineered, reproduced or distributed in any form by any means, or stored in a database or retrieval system, without the prior written permission of S&P Global Market Intelligence or its affiliates (collectively, S&P Global). The Content shall not be used for any unlawful or unauthorized purposes. S&P Global and any third-party providers, as well as their directors, officers, shareholders, employees or agents (collectively S&P Global Parties) do not guarantee the accuracy, completeness, timeliness or availability of the Content. S&P Global Parties are not responsible for any errors or omissions (negligent or otherwise), regardless of the cause, for the results obtained from the use of the Content, or for the security or maintenance of any data input by the user. The Content is provided on an "as is" basis. S&P GLOBAL PARTIES DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING, BUT NOT LIMITED TO, ANY WARRANTIES OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE OR USE, FREEDOM FROM BUGS, SOFTWARE ERRORS OR DEFECTS, THAT THE CONTENT’S FUNCTIONING WILL BE UNINTERRUPTED OR THAT THE CONTENT WILL OPERATE WITH ANY SOFTWARE OR HARDWARE CONFIGURATION. In no event shall S&P Global Parties be liable to any party for any direct, indirect, incidental, exemplary, compensatory, punitive, special or consequential damages, costs, expenses, legal fees, or losses (including, without limitation, lost income or lost profits and opportunity costs or losses caused by negligence) in connection with any use of the Content even if advised of the possibility of such damages.

Credit-related and other analyses, including ratings, and statements in the Content are statements of opinion as of the date they are expressed and not statements of fact. S&P Global Market Intelligence’s opinions, analyses and rating acknowledgment decisions (described below) are not recommendations to purchase, hold, or sell any securities or to make any investment decisions, and do not address the suitability of any security. S&P Global Market Intelligence assumes no obligation to update the Content following publication in any form or format. The Content should not be relied on and is not a substitute for the skill, judgment and experience of the user, its management, employees, advisors and/or clients when making investment and other business decisions. S&P Global Market Intelligence does not act as a fiduciary or an investment advisor except where registered as such. While S&P Global Market Intelligence has obtained information from sources it believes to be reliable, S&P Global Market Intelligence does not perform an audit and undertakes no duty of due diligence or independent verification of any information it receives.

S&P Global keeps certain activities of its divisions separate from each other in order to preserve the independence and objectivity of their respective activities. As a result, certain divisions of S&P Global may have information that is not available to other S&P Global divisions. S&P Global has established policies and procedures to maintain the confidentiality of certain non-public information received in connection with each analytical process.

S&P Global Ratings does not contribute to or participate in the creation of credit scores generated by S&P Global Market Intelligence. Lowercase nomenclature is used to differentiate S&P Global Market Intelligence PD credit model scores from the credit ratings issued by S&P Global Ratings.

S&P Global may receive compensation for its ratings and certain analyses, normally from issuers or underwriters of securities or from obligors. S&P Global reserves the right to disseminate its opinions and analyses. S&P Global's public ratings and analyses are made available on its Web sites, www.standardandpoors.com (free of charge), and www.capitaliq.com (subscription), and may be distributed through other means, including via S&P Global publications and third-party redistributors. Additional information about our ratings fees is available at www.standardandpoors.com/usratingsfees.
Regulatory News Service data provided by 
